1
|
Guzel S, Gunes N, Yildiz H, Yilmaz B. Effects of amylin on bone development and egg production in hens. Poult Sci 2009; 88:1719-24. [PMID: 19590088 DOI: 10.3382/ps.2008-00256] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Amylin is a member of the calcitonin family of hormones cosecreted with insulin from the pancreatic beta-cells that can act as an osteoblast mitogen and as an inhibitor of bone resorption in mice and humans. The aim of this study was to investigate the role of amylin on bone formation and some egg parameters in hens. The study was performed in 60 hens aged 10 wk. Thirty hens constituting the treatment group were s.c. injected with amylin at a 75 microg/kg dose every other day. The remaining hens were used as the control group. Five birds from the treatment and control groups were slaughtered at 14, 16, 18, and 20 wk of age and serum and bone parameters were compared between the treatment and control groups. The remaining 20 hens were fed without any amylin injection until 35 wk. All hens at the end of the 35th week were slaughtered and then serum, bone, and egg parameters were assessed. In the treatment group, bone calcium levels increased, whereas serum calcium levels decreased. This dose of amylin also increased the cortical width of tibiotarsuses in hens. Eggshell thickness was found thicker in the treatment group than in the control group. Overall, the results of this study suggest that amylin may stimulate the bone and eggshell quality by increasing calcium uptake from the bloodstream and may influence the sustainability of yield in hens.
Collapse
Affiliation(s)
- S Guzel
- Department of Biochemistry, University of Uludag, Gorukle Campus, 16059, Bursa, Turkey.
| | | | | | | |
Collapse
|
2
|
Affiliation(s)
- Ian R Reid
- Department of Medicine, University of Auckland, Auckland, New Zealand.
| | | | | |
Collapse
|
3
|
Young A. Amylin and the integrated control of nutrient influx. ADVANCES IN PHARMACOLOGY (SAN DIEGO, CALIF.) 2005; 52:67-77. [PMID: 16492541 DOI: 10.1016/s1054-3589(05)52004-0] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/05/2022]
Abstract
The most potent actions of amylin that occur at physiological plasma concentrations include inhibition of food intake, gastric emptying, acid and digestive enzyme secretion, and glucagon secretion. These actions share a common outcome; they each help regulate the rate at which nutrients (including glucose) appear in the blood (Ra). Amylin physiologically orchestrates, via several parallel processes, the rate of entry of nutrient into the circulation, as shown schematically in Fig. 1. In this way, amylin's function may be viewed as complementary to that of insulin (secreted from the same pancreatic beta-cells), which orchestrates the exit of nutrient from blood and its storage in peripheral tissues. The following discussion addresses the emerging picture that, although amylin is co-secreted with an endocrine hormone from endocrine tissue (the pancreatic islets), the target for its most potent and physiologically relevant effects appears to be the central nervous system. Amylin thus may be primarily regarded as a neuroendocrine hormone (Young et al., 2000).
Collapse
Affiliation(s)
- Andrew Young
- Amylin Pharmaceuticals, Inc., San Diego, California, USA
| |
Collapse
|
4
|
Abstract
Amylin bound to kidney cortex in a distinctive pattern. Binding appeared specific in that it was displaceable with amylin antagonists. It was associated with activation of cyclic AMP (cAMP), and was thereby likely to represent receptor binding and activation. Amylin's principal effects at the kidney included a stimulation of plasma renin activity, reflected in aldosterone increases at quasi-physiological amylin concentrations. It was unclear whether this was a local or a systemic effect. Other renal effects in rats included a diuretic effect and a natriuretic effect. The latter was mainly driven by the diuresis, since urinary sodium concentration did not change. Amylin had a transient effect to lower plasma potassium concentration. This effect was likely to be a consequence of activation of Na+/K+-ATPase, an action shared with insulin and catecholamines. Amylin lowered plasma calcium, particularly ionized calcium, likely due to an antiresorptive effect at osteoclasts. Immunoreactive amylin was detected in the developing kidney. It appeared to have a trophic effect in kidney, and its absence resulted in renal dysgenesis. Neurons in the subfornical organ (SFO), which has a role in fluid/electrolyte homeostasis, were potently activated by amylin. The dipsogenic and renal effects of amylin may be related to effects at the SFO.
Collapse
Affiliation(s)
- Andrew Young
- Amylin Pharmaceuticals, Inc., San Diego, California, USA
| |
Collapse
|
5
|
Abstract
The actions of amylin on bone have been reviewed in several publications (MacIntyre, 1992a,b; MacIntyre et al., 1991; Reid and Cornish, 1996; Tamura et al., 1992a,b; Zaidi et al., 1990a,c, 1993b). MacIntyre proposed that amylin or its derivatives or agonists would be useful for treating bone disorders, such as osteoporosis, Paget's disease, or bone loss resulting from malignancy, endocrine disorders, autoimmune arthritides, breakage and fracture, immobility and disease, or hypercalcaemia (MacIntyre, 1995).
Collapse
Affiliation(s)
- Andrew Young
- Amylin Pharmaceuticals, Inc., San Diego, California, USA
| |
Collapse
|
6
|
Samonina G, Kopylova G, Lukjanzeva G, Zhuykova S, Smirnova E, German S, Guseva A. Antiulcer effects of amylin: a review. PATHOPHYSIOLOGY 2004; 11:1-6. [PMID: 15177509 DOI: 10.1016/j.pathophys.2003.10.008] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2002] [Accepted: 10/09/2003] [Indexed: 01/22/2023] Open
Abstract
Amylin belongs to the calcitonin peptide family. Amylin is a peptide synthesized not only in the beta cells of pancreatic islets, but in small quantities also in other organs like in the intestinal and gastric mucosa, lungs and central nervous system. It is located in the same secretory granules as insulin. Amylin participates in the maintenance of glucose and calcium homeostasis. It also inhibits food intake and decreases body weight. Furthermore, amylin inhibits gastric acid secretion. It protects the gastric mucosa in ulcer models like stress, vagal stimulation, ethanol, acetic acid, reserpine and serotonine administration and pylorus ligation. This protective antiulcer is seen not only at pharmacological but also at near-physiological doses-0.5mkg/kg. Moreover amylin also exerts curative properties in the acetic acid and indomethacin ulcer models. Amylin decreases the aggressive factors like acid-pepsin secretion, increases mast cell stability and increases protective mechanisms like bicarbonate gastric secretion, dilates blood vessels, and it increases lymphatic mesenteric activity. Amylin seems to be a powerful protector of gastric mucosa in animals by increasing the stability of gastric mucosa. Further research remains, however, to be done.
Collapse
Affiliation(s)
- G.E. Samonina
- Department of Human and Animal Physiology, School of Biology, Moscow State Lomonosov University, Vorobjevy Gory 1, Building 12, Moscow 119899, Russia
| | | | | | | | | | | | | |
Collapse
|
7
|
Horcajada-Molteni MN, Chanteranne B, Lebecque P, Davicco MJ, Coxam V, Young A, Barlet JP. Amylin and bone metabolism in streptozotocin-induced diabetic rats. J Bone Miner Res 2001; 16:958-65. [PMID: 11341342 DOI: 10.1359/jbmr.2001.16.5.958] [Citation(s) in RCA: 92] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Amylin (AMY) is a 37 amino acid peptide cosecreted with insulin (INS) by pancreatic beta-cells and absent in type 1 diabetes, a condition frequently associated with osteopenia. AMY binds to calcitonin receptors, lowers plasma calcium concentration, inhibits osteoclast activity, and stimulates osteoblasts. In the present study, we examined the effects of AMY replacement on bone loss in a streptozotocin (STZ)-induced rodent model type 1 diabetes. Of 50 male Wistar rats studied, 40 were made diabetic with intraperitoneal STZ (50 mg/kg; plasma glucose concentrations > 11 mM within 5 days). Ten nondiabetic control (CONT) rats received citrate buffer without STZ. Diabetic rats were divided into four groups (n = 10/group) and injected subcutaneously with rat AMY (45 mg/kg), INS (12 U/kg), both (same doses), or saline (STZ; diabetic controls) once per day. After 40 days of treatment and five 24-h periods of urine collection for deoxypyridinoline (DPD), the animals were killed, blood was sampled, and femurs were removed. The left femur was tested for mechanical resistance (three-point bending). The right femur was tested for total, diaphyseal (cortical bone), and metaphyseal (trabecular bone) bone densities using dual-energy X-ray absorptiometry (DXA). Bone was ashed to determine total bone mineral (calcium) content. None of the treatments had any significant effect on femoral length and diameter. Untreated diabetic rats (STZ; 145+/-7N) had lower bone strength than did nondiabetic CONT (164+/-38; p < 0.05). Total bone mineral density (BMD; g/cm2) was significantly lower in STZ (0. 2523+/-0.0076) than in CONT (0.2826+/-0.0055), as were metaphyseal and diaphyseal densities. Diabetic rats treated with AMY, INS, or both had bone strengths and bone densities that were indistinguishable from those in nondiabetic CONT. Changes in bone mineral content paralleled those for total BMD (T-BMD). Plasma osteocalcin (OC) concentration, a marker for osteoblastic activity, was markedly lower in untreated diabetic rats (7. 6+/-0.9 ng/ml); p < 0.05) than in nondiabetic CONT (29.8+/-1.7; p < 0.05) or than in AMY (20.1+/-0.7; p < 0.05). Urinary DPD excretion, a marker for bone resorption, was similar in untreated and AMY-treated diabetic rats (35.0+/-3.1 vs. 35.1+/-4.4 nmol/mmol creatinine), intermediate in rats treated with INS (49.9+/-2.7), and normalized in diabetic rats treated with both agents (58.8+/-8.9 vs. 63.2+/-4.5 in CONT). Thus, in our STZ rat model of diabetic osteopenia, addition of AMY improved bone indices apparently by both inhibiting resorption and stimulating bone formation.
Collapse
Affiliation(s)
- M N Horcajada-Molteni
- Métabolisme Minéral-U3M, Institut National de la Recherche Agronomique, St. Genës Champanelle, France
| | | | | | | | | | | | | |
Collapse
|
8
|
Sibilia V, Pagani F, Lattuada N, Rapetti D, Guidobono F, Netti C. Amylin compared with calcitonin: competitive binding studies in rat brain and antinociceptive activity. Brain Res 2000; 854:79-84. [PMID: 10784109 DOI: 10.1016/s0006-8993(99)02286-6] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Binding studies for rat amylin (AMY) and salmon calcitonin (sCT) were performed on rat membranes prepared from pons and medulla oblongata of rats. The aim was to see whether specific binding sites for AMY and/or for sCT present in these areas could be relevant to some of the biological activities of the two peptides. Binding sites specific for [125I]AMY are present in the pons-medulla of rat brain as AMY, but not sCT, was able to displace radiolabeled AMY binding with an IC50 = 3.7+/-0.5x10(-10) M. In contrast, binding of [125I]sCT was displaced by both sCT and AMY, although with different potencies, the IC50 for sCT being 1+/-0.1x10(-11) M, and for AMY, 1.8+/-0.08x10(-7) M. The functional significance of the presence of these binding sites was evaluated in two different nociceptive tests, hot-plate and tail-flick. In the tail-flick test neither AMY (5-10 microg/rat, i.c.v.) nor sCT (10 microg/rat i.c.v.) showed antinociceptive activity, whereas in the hot-plate test AMY (10 microg/rat, i.c.v.) significantly increased the response latencies as did sCT (250 ng/rat, i.c.v.). These results demonstrated that a 40-fold greater dose of AMY is necessary to produce a comparable antinociceptive effect to that exerted by sCT. These findings are in accordance with the low affinity of AMY for sCT binding sites in rat pons-medulla. It is therefore suggested that the central inhibitory activity of AMY on pain perception involves interaction with sCT receptors whereas the selective AMY binding sites subserve other (as yet unknown) functions.
Collapse
Affiliation(s)
- V Sibilia
- Department of Pharmacology, Chemotherapy and Medical Toxicology, University of Milano, Milan, Italy.
| | | | | | | | | | | |
Collapse
|
9
|
Hazewinkel HA, Schoenmakers I, Pelling D, Snijdelaar M, Wolfswinkel J, Mol JA. Biological potency and radioimmunoassay of canine calcitonin. Domest Anim Endocrinol 1999; 17:333-44. [PMID: 10628425 DOI: 10.1016/s0739-7240(99)00058-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Calcitonin (CT) is a major calcitropic hormone. Because of low cross reactivity of canine CT (cCT) in radioimmunoassays (RIA) developed for other species, a homologous RIA is needed. Synthesis of cCT allowed study of its biologic potency using a rat bioassay and its plasma half-life in dogs. The availability of cCT also made possible the development of a homologous RIA for measurement of basal and stimulated plasma CT concentrations in dogs. The biologic potency of the synthesized cCT in rats is 24 IU/mg of peptide, which is low in comparison with the 4,000 IU/mg of the salmon CT standard. In the dog, an even lower potency of 4.4 IU/mg of cCT was found. Measurement of the disappearance of iv-injected radioiodinated or nonradioiodinated cCT revealed a short biologic half-life of less than 3 min, followed by a long half-life of 20 min. A polyclonal antiserum against synthetic cCT was raised in a goat. Using a final antiserum dilution of 1:12,000 and 125I-labeled synthetic cCT, the RIA had a detection limit of 6.5 ng/l. The antibody did not crossreact with standard human CT and had <0.1% cross reactivity with porcine CT. For measurement of plasma cCT concentrations, an extraction procedure was developed using ethanol. Dilutions of synthetic cCT and canine plasma extracts revealed parallelism over a wide range of concentrations. Size exclusion chromatography of canine plasma extracts on Biogel P-10 revealed a single cCT peak at the same position as [125I]-cCT, showing that there was little interference by other proteins or cCT prohormone. Basal plasma CT concentrations were 12-80 ng/l, and there was an 8- and 20-fold increase after calcium (1 and 2.5 mg/kg body weight) bolus infusion.
Collapse
Affiliation(s)
- H A Hazewinkel
- Department of Clinical Science, Companion Animals, Utrecht, The Netherlands.
| | | | | | | | | | | |
Collapse
|
10
|
Wookey PJ, Cooper ME. Amylin: physiological roles in the kidney and a hypothesis for its role in hypertension. Clin Exp Pharmacol Physiol 1998; 25:653-60. [PMID: 9750952 DOI: 10.1111/j.1440-1681.1998.tb02272.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
1. There are high-affinity binding sites for amylin in the renal cortex associated with proximal tubules. These appear to represent seven transmembrane (heptatopic) receptors that are known to form ternary complexes with G-proteins and activate second messenger systems. 2. Amylin stimulates sodium/water reabsorption from the basolateral side of the proximal tubules and plays a role in sodium homeostasis. 3. The transient expression of amylin-like mRNA has been detected perinatally, using in situ hybridization, in the subnephrogenic zone of the metanephros and is associated with proximal tubules of the developing nephron. There it is thought to play a role as a growth factor for brush border epithelial cells in the developing kidney and in renal regrowth in the adult kidney. 4. In two models of hypertension, the spontaneously hypertensive rat (SHR) and one created surgically by subtotal nephrectomy, renal amylin receptors are activated. In the SHR, activation precedes the rise in blood pressure and suggests that activation of the amylin system may be an important event in the development of hypertension.
Collapse
Affiliation(s)
- P J Wookey
- Department of Medicine, University of Melbourne, Austin & Repatriation Medical Centre, West Heidelberg, Victoria, Australia.
| | | |
Collapse
|
11
|
Cornish J, Callon KE, Lin CQ, Xiao CL, Mulvey TB, Coy DH, Cooper GJ, Reid IR. Dissociation of the effects of amylin on osteoblast proliferation and bone resorption. THE AMERICAN JOURNAL OF PHYSIOLOGY 1998; 274:E827-33. [PMID: 9612240 DOI: 10.1152/ajpendo.1998.274.5.e827] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
This study assesses the structure-activity relationships of the actions of amylin on bone. In fetal rat osteoblasts, only intact amylin and amylin-(1-8) stimulated cell proliferation (half-maximal concentrations 2.0 x 10(-11) and 2.4 x 10(-10) M, respectively). Amylin-(8-37), COOH terminally deamidated amylin, reduced amylin, and reduced amylin-(1-8) (reduction results in cleavage of the disulfide bond) were without agonist effect but acted as antagonists to the effects of both amylin and amylin-(1-8). Calcitonin gene-related peptide-(8-37) also antagonized the effects of amylin and amylin-(1-8) on osteoblasts but was substantially less potent in this regard than amylin-(8-37). In contrast, inhibition of bone resorption in neonatal mouse calvariae only occurred with the intact amylin molecule and was not antagonized by any of these peptides. The rate of catabolism of the peptides in calvarial cultures was not accelerated in comparison with that of intact amylin. This dissociation of the actions of amylin suggests that it acts through two separate receptors, one on the osteoclast (possibly the calcitonin receptor) and a second on the osteoblast.
Collapse
Affiliation(s)
- J Cornish
- Department of Medicine, University of Auckland, New Zealand
| | | | | | | | | | | | | | | |
Collapse
|